In the STEP-1 trial published in The New England Journal of Medicine in 2021, once-weekly subcutaneous semaglutide at 2.4 mg produced a mean placebo-adjusted body weight reduction of 12.4% at 68 weeks in adults with overweight or obesity (Wilding et al., NEJM, 2021)
These medications are the brand names drugs behind Semaglutide and Tirzepatide and vary in dose, FDA-approved indications, and expected weight outcomes
ChoFlpIn stable cell lines generation The wild-type (WT) and mutant cMyc-GLP-1R 4 constructs containing designed signal alanine mutation were integrated into CHOFlpIn cells using the FlpIn Gateway technology system (Invitrogen)
Reduced platelet activation markers
Its important to remember that weight loss takes time, and youll have the best results if you use Ozempic in combination with exercise and a healthy diet
Image analyses were done using Harmony software v5.0 (Revvity) and detailed steps are further described in Supplementary Table S1